Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia.
Promising results in the treatment of indolent lymphomas have been reported with the use of 2'deoxycoformycin. This antimetabolite, an adenosine deaminase inhibitor, also shows particular efficacy in hairy cell leukemia. Of 65 patients treated to date, 44 have achieved complete and lasting remission after a limited course of deoxycoformycin. While results are not as striking as those in hairy cell leukemia, deoxycoformycin may also be a valuable adjunct to alkylating agents in the treatment of CLL. The drug also is being studied in the treatment of mycosis fungoides and other lymphoid neoplasms. Side effects in all neoplasms are dose- and schedule-dependent.
O'Dwyer
P J
PJ
Fox Chase Cancer Center, Philadelphia, PA 19111.
Cheson
B D
BD
Leyland-Jones
B
B
King
S A
SA
Hoth
D F
DF
D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D009182:Mycosis Fungoides / Q000188:drug therapy; D015649:Pentostatin / Q000009:adverse effects / Q000627:therapeutic use*
D015649:Pentostatin